Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3845260

CS(N)(=O)=O.O=C(O)C(F)(F)F

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 8/20 0.47
ALDH1A1 P00352 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CA2 P00918 7/20 0.40
CA7 P43166 3/20 0.40
CA13 Q8N1Q1 2/20 0.40
CA9 Q16790 6/20 0.35
CA12 O43570 4/20 0.35
TSHR P16473 2/20 0.33
ATR Q13535 1/20 0.33
CA5A P35218 3/20 0.32
CA4 P22748 2/20 0.32
CA6 P23280 2/20 0.32
CA5B Q9Y2D0 2/20 0.32
NT5E P21589 1/20 0.32
NOS1 P29475 1/20 0.32
NOS2 P35228 1/20 0.32
THRB P10828 1/20 0.31
MAPT P10636 1/20 0.30
CA3 P07451 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL30657138 1.00 CA1 (0.47) CA1ALDH1A1L3MBTL1CA2CA7
Trifluoroacetic Acid SCHEMBL30605511 0.88 ALDH1A1 (0.48) CA1ALDH1A1L3MBTL1CA2CA7
Trifluoroacetic Acid SCHEMBL144167 0.85 ALDH1A1 (0.52) CA1ALDH1A1L3MBTL1CA2CA7
Trifluoroacetic Acid SCHEMBL28219947 0.83 ALDH1A1 (0.40) CA1ALDH1A1L3MBTL1CA2CA7
Trifluoroacetic Acid SCHEMBL28849341 0.82 ALDH1A1 (0.50) CA1ALDH1A1L3MBTL1CA2CA7
Trifluoromethanesulfonamide SCHEMBL2333486 0.82 CA1 (0.65) CA1ALDH1A1L3MBTL1CA2CA7
Trifluoroacetic Acid SCHEMBL21632604 0.82 ALDH1A1 (0.50) CA1ALDH1A1L3MBTL1CA2CA7
Trifluoroacetic Acid SCHEMBL1731636 0.81
Trifluoroacetic Acid SCHEMBL29615579 0.81 ALDH1A1 (0.41) ALDH1A1L3MBTL1CA2TSHRNOS1
Trifluoroacetic Acid SCHEMBL5245971 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106941019-A Electric conductor, its manufacture method and the electronic installation including it 三星电子株式会社 2017-07-11 CN claimed
WO-2025081019-A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS, INC. (US) 2025-04-17 WO disclosed
CN-119585252-A Bicyclic heteroaryl containing compounds as IKZF2 degrading agents 翁科皮亚治疗公司和SK生命科学实验室 2025-03-07 CN disclosed
WO-2024227104-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BRAF VIA UBIQUITIN PROTEOSOME PATHWAY NURIX THERAPEUTICS, INC. (US) 2024-10-31 WO disclosed
CN-118005640-A GCN2 inhibitors and uses thereof 默克专利股份有限公司 2024-05-10 CN disclosed
CN-111918651-B GCN2 inhibitors and uses thereof 默克专利股份有限公司 2024-01-30 CN disclosed
CN-116848091-A Inhibitors of ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP 1) and uses thereof 1CBIO公司 2023-10-03 CN disclosed
WO-2023174406-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2023-09-21 WO disclosed
US-20230266321-A1 LIVE CELL ENGAGEMENT ASSAY ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2023-08-24 US disclosed
CN-116323624-A Quinazoline compound and application thereof 上海医药集团股份有限公司 2023-06-23 CN disclosed
WO-2022068921-A1 QUINAZOLINE COMPOUND AND APPLICATION THEREOF 上海医药集团股份有限公司 2022-04-07 WO disclosed
CN-105339332-B Cycloalkanes oxidation catalyst and the method for production alcohol and ketone 罗地亚经营管理公司 2018-04-10 CN disclosed
CN-105339332-B Cycloalkanes oxidation catalyst and the method for production alcohol and ketone 罗地亚经营管理公司 2018-04-10 CN disclosed
US-9761532-B2 Hybrid interconnect structure and electronic device employing the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2017-09-12 US disclosed
CN-106941019-A Electric conductor, its manufacture method and the electronic installation including it 三星电子株式会社 2017-07-11 CN disclosed
US-20170092592-A1 HYBRID INTERCONNECT STRUCTURE AND ELECTRONIC DEVICE EMPLOYING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2017-03-30 US disclosed
CN-105339332-A Cycloalkane oxidation catalysts and method to produce alcohols and ketones RHODIA OPERATIONS 2016-02-17 CN disclosed
EP-2054053-A1 BIPHENYL SUBSTITUTED SPIROTETRONIC ACIDS AND THEIR USE FOR THE TREATMENT OF RETROVIRAL DISORDERS AiCuris GmbH & Co. KG (DE) 2009-05-06 EP disclosed
WO-2008022725-A1 BIPHENYL SUBSTITUTED SPIROTETRONIC ACIDS AND THEIR USE FOR THE TREATMENT OF RETROVIRAL DISORDERS AICURIS GMBH & CO. KG (DE) 2008-02-28 WO disclosed
WO-2005004796-A2 SULFONYLAMINO PHENYLACETAMIDE DERIVATIVES AND METHODS OF THEIR USE ADOLOR CORPORATION (US) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230266321-A1 LIVE CELL ENGAGEMENT ASSAY KSR1, KSR2, ARAF CA1 4506/4885ALDH1A1 4413/4885L3MBTL1 1077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.